Targeting co-stimulatory molecules in autoimmune disease

Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T lymphocyte antigen 4 (CTLA4) and PD1, both of which are members of the CD28 family. In autoimmunity, these same pathways can...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2020-12, Vol.19 (12), p.860-883
Hauptverfasser:	Edner, Natalie M., Carlesso, Gianluca, Rush, James S., Walker, Lucy S. K.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/1619/554 631/250/38 Autoimmune diseases Autoimmune Diseases - immunology Autoimmune Diseases - therapy Biomedical and Life Sciences Biomedicine Biotechnology Cancer Cancer Research CD28 Antigens - antagonists & inhibitors CTLA-4 Antigen - antagonists & inhibitors Development and progression Drug therapy Enzyme inhibitors Genetic aspects Health aspects Humans Immunotherapy Immunotherapy - methods Inducible T-Cell Co-Stimulator Protein - antagonists & inhibitors Medicinal Chemistry Methods Molecular Medicine Molecular targeted therapy Patient outcomes Pharmacology/Toxicology Receptors, OX40 - antagonists & inhibitors Review Article Signal Transduction Tumor antigens Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!